What is the mechanism of action of ibrutinib/Eco and what is its principle?

Ibrutinib/Ibrutinib (Ibrutinib) is an oral targeted drug that is a Bruton's tyrosine kinase (BTK) inhibitor. It specifically inhibits the activity of BTK and blocks B cell receptor signaling, thereby controlling the growth and expansion of B cell-related malignant tumors. BTK is a tyrosine kinase widely expressed in B cells and some immune cells, and is involved in signal transduction after B cell receptor (BCR) activation.

In the normal physiological function of B cells, the activation of BCR receptors will trigger the activation of BTK, which will then activate downstream signaling pathways to promote B cell proliferation, differentiation and antibody production. Especially in the immune response, the role of BTK is crucial. However, in many B cell-related malignancies, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia, the BCR signaling pathway is abnormally activated, allowing cancer cells to escape apoptosis and continue to proliferate.

Ibrutinib binds to the active site of BTK to form a covalent bond, inhibits the tyrosine kinase activity of BTK and blocks its role in the BCR signaling pathway. Since BCR signaling is critical for B cell growth and survival, inhibiting the activity of BTK can effectively inhibit the proliferation of tumor cells, thereby slowing or stopping cancer progression. Unlike traditional chemotherapy, ibrutinib's mechanism of action is highly targeted, so it causes less damage to normal cells during treatment and has relatively few side effects.

In addition to inhibiting the proliferation of tumor cells, ibrutinib may also further enhance the body's immune response by regulating immune cells in the tumor microenvironment, which has a positive auxiliary effect against tumors. Its efficacy is not limited to inhibiting the proliferation of tumor cells, but also includes improving the anti-tumor ability of the patient's immune system by changing the tumor immune microenvironment.

Reference materials:https://www.imbruvica.com/